# Direct sputum sensitivity testing (DSST) in cystic fibrosis

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
12/09/2003	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
12/09/2003	Completed	Results
Last Edited	Condition category	Individual participant data
16/03/2016	Nutritional, Metabolic, Endocrine	Record updated in last year

### Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr David Serisier

#### Contact details

Adult Cystic Fibrosis Unit, Level D, West Wing (Room WD48) Southampton General Hospital Tremona Road Southampton United Kingdom SO16 6YD +44 (0)23 80794719 dserisier@hotmail.com

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

N0231103375

# Study information

#### Scientific Title

Direct sputum sensitivity testing (DSST) in cystic fibrosis

### **Study objectives**

Does direct sputum sensitivity testing in cystic fibrosis patients alter antibiotic prescribing and improve clinical outcomes?

### Ethics approval required

Old ethics approval format

# Ethics approval(s)

Not provided at time of registration

### Study design

Randomised double blinf controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Diagnostic

### Participant information sheet

# Health condition(s) or problem(s) studied

Cystic fibrosis

#### Interventions

Double blind, randomised controlled trial of DSST versus usual antibiotic sensitivity testing in cystic fibrosis patients with infective exacerbations requiring IV antibiotics.

### **Intervention Type**

Other

#### Phase

**Not Specified** 

### Primary outcome measure

Duration of IV antibiotic therapy.

# Secondary outcome measures

- 1. Lung function
- 2. Quality of life
- 3. Antibiotic drug costs.

### Overall study start date

01/04/2001

# Completion date

31/03/2006

# **Eligibility**

### Key inclusion criteria

Cystic fibrosis patients (with infective exacerbations requiring IV antibiotics) who are colonised with Pseudonomas or Burkholderia.

# Participant type(s)

**Patient** 

### Age group

**Not Specified** 

#### Sex

**Not Specified** 

### Target number of participants

Not provided at time of registration

### Key exclusion criteria

Does not meet inclusion criteria

### Date of first enrolment

01/04/2001

### Date of final enrolment

31/03/2006

# Locations

### Countries of recruitment

England

United Kingdom

# Study participating centre

### Adult Cystic Fibrosis Unit, Southampton United Kingdom SO16 6YD

# Sponsor information

### Organisation

Department of Health (UK)

### Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

### Sponsor type

Government

#### Website

http://www.doh.gov.uk

# Funder(s)

# Funder type

Hospital/treatment centre

### **Funder Name**

Southampton University Hospitals NHS Trust (UK)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration